-
公开(公告)号：US20240158454A1
公开(公告)日：2024-05-16
申请号：US18492141
申请日：2023-10-23
CPC分类号： C07K14/4705 , A61P35/00 , C07K16/22 , A61K2039/542
摘要： The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
-
公开(公告)号：US20240024275A1
公开(公告)日：2024-01-25
申请号：US18144890
申请日：2023-05-09
发明人： Tarek A. Zeidan , Scott Duncan , Christopher P. Hencken , Thomas Andrew Wynn , Carlos N. Sanrame
IPC分类号： C07C233/90
CPC分类号： C07C233/90
摘要： The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
-
公开(公告)号：US20230302008A1
公开(公告)日：2023-09-28
申请号：US17820783
申请日：2022-08-18
发明人： Randall J. MACK , Alex FREYER
CPC分类号： A61K31/5415 , A61K9/10 , A61K9/0019 , A61P29/00 , A61K47/28 , A61K47/32 , A61P25/00
摘要： The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.
-
公开(公告)号：US20230293505A1
公开(公告)日：2023-09-21
申请号：US18136120
申请日：2023-04-18
发明人： Sean Cunningham , Seamus Mulligan , Michael Myers
CPC分类号： A61K31/4409 , A61K9/2054 , A61K31/44 , A61K9/2077 , A61K47/14 , A61K47/38 , A61K47/44 , A61K47/12 , A61K9/20
摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
-
公开(公告)号：US11717481B2
公开(公告)日：2023-08-08
申请号：US17542276
申请日：2021-12-03
发明人： Niels P. Ryde , Peter Snyder , Wei Liu , David M. Slifer
IPC分类号： A61K9/16 , A61K9/00 , A61K9/14 , A61K31/5415 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/28 , A61K47/32
CPC分类号： A61K9/1623 , A61K9/0019 , A61K9/10 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1688 , A61K31/5415 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/28 , A61K47/32
摘要： This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
-
公开(公告)号：US20220142999A1
公开(公告)日：2022-05-12
申请号：US17588133
申请日：2022-01-28
发明人： Sean Cunningham , Seamus Mulligan , Michael Myers
摘要： A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
-
公开(公告)号：US11273158B2
公开(公告)日：2022-03-15
申请号：US16291768
申请日：2019-03-04
IPC分类号： A61K31/497 , A61P25/18 , A61K47/12 , A61K47/26 , A61K31/496 , A61K47/02 , A61K9/00
摘要： The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
-
公开(公告)号：US11185541B2
公开(公告)日：2021-11-30
申请号：US16899708
申请日：2020-06-12
发明人： Daniel R. Deaver , Mark Todtenkopf
IPC分类号： A61K31/485 , A61K31/439 , A61K31/496 , A61K31/519 , A61K31/5513 , A61K31/554 , C07D221/28 , C07D405/06 , A61K9/20 , A61K31/551
摘要： The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
-
公开(公告)号：US20210338656A1
公开(公告)日：2021-11-04
申请号：US17231307
申请日：2021-04-15
摘要： The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor.
-
公开(公告)号：US20210196703A1
公开(公告)日：2021-07-01
申请号：US17063892
申请日：2020-10-06
发明人： Daniel R. Deaver , Elliot Ehrich
IPC分类号： A61K31/4748 , A61K45/06 , A61K31/485 , A61K9/00
摘要： The invention relates to a composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; A A nAI = [ C m ax ( BUP ) / EC 50 ] [ C ma x ( ANTAGONIST ) / IC 50 ] .
-
-
-
-
-
-
-
-
-
搜索结果
252 条记录 (耗时 0.06 秒)
